{"entity":{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","aka":[],"tldr":"Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard.","summary":"Pierre Fenaux (Hôpital Saint-Louis, Paris) was principal investigator of AZA-001, the trial that showed azacitidine improves overall survival compared with conventional care in higher-risk myelodysplastic syndromes, the first drug to do so and the foundation of hypomethylating therapy in MDS and AML. He co-led the European APL trials with Laurent Degos that established all-trans retinoic acid and leads the Groupe Francophone des Myélodysplasies.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenaux%20P%5BAuthor%5D%20azacitidine%20myelodysplastic"}],"tags":["mds","epigenetics","france"],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":["epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":["aphp-nord-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-imerge-imetelstat-mds-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Hematology, Hôpital Saint-Louis, Université Paris Cité","institutionId":"aphp-nord-cancer-institute","specialisms":["Myelodysplastic syndromes","Hypomethylating agents","Acute promyelocytic leukaemia","Older patients with AML"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fenaux%20P%5BAuthor%5D%20azacitidine%20myelodysplastic"}],"papers":[{"title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001)","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(09)70003-8"},{"title":"Myelodysplastic syndromes","journal":"Lancet","year":2014},{"title":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IMerge%20imetelstat%20lower-risk%20MDS%20Platzbecker%20Lancet%202024"}]},"route":"/people/pierre-fenaux/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"institution":[{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/"}],"paper":[{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}],"trial":[{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/"},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/"}]}}